Sutro Biopharma, Inc. financial data

Symbol
STRO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
111 Oyster Point Blvd., South San Francisco, California
Fiscal year end
December 31
Former names
Fundamental Applied Biology Inc (to 10/24/2007)
Latest financial report
Q1 2024 - May 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 500 % -14.3%
Debt-to-equity 244 % +189%
Return On Equity -89.3 % -44.4%
Return On Assets -26 % +22.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 62.4 M shares +3.79%
Common Stock, Shares, Outstanding 62.5 M shares +3.81%
Entity Public Float 278 M USD +11%
Common Stock, Value, Issued 62 K USD +3.33%
Weighted Average Number of Shares Outstanding, Basic 61.5 M shares +4.66%
Weighted Average Number of Shares Outstanding, Diluted 61.5 M shares +4.66%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 154 M USD +107%
Research and Development Expense 198 M USD +35%
General and Administrative Expense 59.8 M USD -0.37%
Operating Income (Loss) -104 M USD +21.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -97.2 M USD +23.6%
Income Tax Expense (Benefit) 18.2 M USD
Net Income (Loss) Attributable to Parent -115 M USD +11.7%
Earnings Per Share, Basic -1.88 USD/shares +20.3%
Earnings Per Share, Diluted -1.88 USD/shares +20.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 65.2 M USD +4.4%
Marketable Securities, Current 202 M USD +7.09%
Accounts Receivable, after Allowance for Credit Loss, Current 31.3 M USD +217%
Assets, Current 355 M USD +16.6%
Property, Plant and Equipment, Net 20.6 M USD -14.1%
Operating Lease, Right-of-Use Asset 21.6 M USD -16.3%
Other Assets, Noncurrent 5.74 M USD +76.6%
Assets 403 M USD +12.7%
Accounts Payable, Current 7.51 M USD +48.5%
Accrued Liabilities, Current 7.08 M USD +11.3%
Contract with Customer, Liability, Current 20.5 M USD +19.3%
Liabilities, Current 79.5 M USD +33.7%
Contract with Customer, Liability, Noncurrent 46.3 M USD -45.5%
Operating Lease, Liability, Noncurrent 21.4 M USD -23.8%
Other Liabilities, Noncurrent 1.69 M USD
Liabilities 305 M USD +76.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -113 K USD -5.61%
Retained Earnings (Accumulated Deficit) -618 M USD -22.9%
Stockholders' Equity Attributable to Parent 98 M USD -47.1%
Liabilities and Equity 403 M USD +12.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -64.7 M USD -6.15%
Net Cash Provided by (Used in) Financing Activities -3.43 M USD -139%
Net Cash Provided by (Used in) Investing Activities 64.1 M USD -4.96%
Common Stock, Shares Authorized 300 M shares 0%
Common Stock, Shares, Issued 62.5 M shares +3.81%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.07 M USD -127%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 66.1 M USD +4.31%
Interest Paid, Excluding Capitalized Interest, Operating Activities 63 K USD -84%
Deferred Tax Assets, Valuation Allowance 168 M USD +27.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross 181 M USD +27%
Operating Lease, Liability 28.1 M USD -15.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -115 M USD +11%
Lessee, Operating Lease, Liability, to be Paid 33.8 M USD -20.2%
Property, Plant and Equipment, Gross 64.1 M USD +2.52%
Operating Lease, Liability, Current 6.67 M USD +27.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 8.99 M USD -5.65%
Lessee, Operating Lease, Liability, to be Paid, Year One 9.53 M USD +3.41%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.7 M USD -36.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.29 M USD -7.84%
Deferred Tax Assets, Operating Loss Carryforwards 37.2 M USD -38.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 8.73 M USD +0.94%
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.29 M USD -7.84%
Operating Lease, Payments 2.3 M USD +35.3%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.76 M USD +9.04%
Deferred Tax Assets, Net of Valuation Allowance 13.1 M USD +17.3%
Share-based Payment Arrangement, Expense 25 M USD -1.56%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%